BIIB

#489
Biogen Inc. Common Stock
180.68 USD
+2.44%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
177.45
180.85
Rango anual
114.66
202.41
Cambio diario
+2.44%
Variación mensual
-1.14%
Variación en los últimos 6 meses
+24.83%
Cambio anual
+51.88%
Cierres anteriores
176.37
Abrir
177.71
Bid
Ask
Mínimo
177.45
High
180.85
Volumen
150
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 26.52 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
20.02
Relación precio/flujo de caja
2.62

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Noticias